Related Experiment Video
Updated: Jun 28, 2026

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Treatment and prognosis of hepatocellular carcinoma: a population based study in France
Frédéric Borie1, Anne-Marie Bouvier, Astrid Herrero
1Registre des Tumeurs de l'Hérault, Centre de Recherche, Montpellier Cedex, France. fborie@yahoo.com
Insights
Hepatocellular carcinoma (HCC) management and prognosis in France show poor outcomes, with most patients receiving limited palliative care. Enhanced prevention strategies are crucial for improving survival rates in HCC patients.
Area of Science:
- Hepatobiliary Medicine
- Oncology
- Epidemiology
Background:
- Limited population-based data exist on hepatocellular carcinoma (HCC) management and prognosis.
- Understanding HCC in a French population is essential for public health initiatives.
Purpose of the Study:
- To report on the management and prognosis of hepatocellular carcinoma (HCC) in a French population.
- To compare clinical presentation, treatment, and survival rates between HCC with and without cirrhosis.
Main Methods:
- Analysis of 1,007 registered HCC cases from 1997-1998 in nine French departments.
- Comparison of clinical presentation and treatment in patients with and without cirrhosis.
- Determination of prognosis using crude and relative survival rates, including multivariate analysis.
Main Results:
- HCC was associated with cirrhosis in 79% of cases and without cirrhosis in 15%.
- Symptoms were the primary discovery mode (63-70%); diagnosis was histologically verified in 50% (cirrhosis) and 80% (no cirrhosis).
- Five-year survival rates were low overall (6-9%), with slightly better outcomes for non-cirrhotic cases (28-29%) versus cirrhotic cases (34-39% for specific treatments, 6% overall). Liver transplant offered 60% 5-year survival in 24 cases.
Conclusions:
- Hepatocellular carcinoma (HCC), with or without cirrhosis, demonstrates a poor prognosis.
- Current treatments are largely palliative and offer limited efficacy.
- Significant advancements in primary and secondary prevention are urgently needed.
Objective:
Few data are available from population-based statistics on hepatocellular carcinoma (HCC). The aim of this study was to report on their management and their prognosis in a French population.
Methods:
Between 1997 and 1998, 1,007 cases of HCC were registered in nine French departments: clinical presentation of patients with and without cirrhosis were compared as well as treatment. Prognosis was determined using crude and relative survival rates. A multivariate relative survival analysis was performed. HCC was associated with cirrhosis in 795 patients (79%) and to the absence of cirrhosis in 156 (15%).
Results:
Whereas the presence of symptoms was the principal mode of discovery (63% of cirrhotic cases and 70% of non-cirrhotic cases), the follow-up of hepatic affections revealed the cancer in respectively 26% and 3% (P = 0.001). The diagnosis was histologically verified in 50% of cirrhotic patients and 80% of non-cirrhotic patients (P = 0.01). The size of tumours was significantly greater in non-cirrhotic than in cirrhotic cases (P = 0.004). Treatment for cure were implemented in respectively 15% and 30% (P = 0.001), resulting in 5-year survival rates of respectively 34% and 28%. Only 24 HCC cases received a liver transplant, with a 5-year survival rate of 60%. Surgical resection for cure was carried out in respectively 10% and 31% of HCC and HCNC cases (P = 0.001), with a 5-year survival rate of respectively 39% and 29%. The overall 5-year survival rates of HCC and HCNC were respectively 6% and 9%.
Conclusion:
HCC with and without cirrhosis has a poor prognosis with the majority of patients receiving palliative treatments, the efficiency of which is very limited. Considerable efforts are needed to develop primary and secondary prevention.
Related Concept Videos
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
